Do analysts rate AVNS or CARL?

Carlsmed has a consensus target price of $18.75, suggesting a potential upside of 58.63%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts clearly believe Carlsmed is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Carlsmed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, CARL or AORT?

Artivion has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 6.36 -$29.63M -$2.51 N/A Artivion $441.33M 2.83 $9.77M $0.24 107.29

Is CARL or AORT more profitable?

Artivion has a net margin of 2.55% compared to Carlsmed's net margin of -57.76%. Artivion's return on equity of 7.15% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.76% -60.74% -29.84% Artivion 2.55% 7.15% 3.63%

Carlsmed (CARL) Competitors

$11.82 +0.74 (+6.68%)

Closing price 04:00 PM Eastern

Extended Trading

$11.66 -0.16 (-1.35%)

As of 07:44 PM Eastern

Compare

CARL vs. PRCT, DRTS, AVNS, AORT, and TNDM

Should you buy Carlsmed stock or one of its competitors? MarketBeat compares Carlsmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carlsmed include PROCEPT BioRobotics (PRCT), Alpha Tau Medical (DRTS), Avanos Medical (AVNS), Artivion (AORT), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.

How does Carlsmed compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PROCEPT BioRobotics has a net margin of -31.82% compared to Carlsmed's net margin of -57.76%. PROCEPT BioRobotics' return on equity of -27.70% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Carlsmed	-57.76%	-60.74%	-29.84%

In the previous week, PROCEPT BioRobotics had 5 more articles in the media than Carlsmed. MarketBeat recorded 6 mentions for PROCEPT BioRobotics and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.94 beat PROCEPT BioRobotics' score of 0.26 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
PROCEPT BioRobotics	Neutral
Carlsmed	Positive

Carlsmed has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.55	-$95.57M	-$1.82	N/A
Carlsmed	$50.51M	6.36	-$29.63M	-$2.51	N/A

PROCEPT BioRobotics presently has a consensus target price of $37.27, indicating a potential upside of 94.13%. Carlsmed has a consensus target price of $18.75, indicating a potential upside of 58.63%. Given PROCEPT BioRobotics' higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

PROCEPT BioRobotics beats Carlsmed on 10 of the 16 factors compared between the two stocks.

How does Carlsmed compare to Alpha Tau Medical?

Carlsmed (NASDAQ:CARL) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Alpha Tau Medical has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Alpha Tau Medical	N/A	-73.23%	-52.90%

Carlsmed presently has a consensus price target of $18.75, suggesting a potential upside of 58.63%. Alpha Tau Medical has a consensus price target of $12.60, suggesting a potential upside of 6.06%. Given Carlsmed's stronger consensus rating and higher probable upside, research analysts plainly believe Carlsmed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

2.7% of Alpha Tau Medical shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Carlsmed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	6.36	-$29.63M	-$2.51	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

In the previous week, Alpha Tau Medical had 4 more articles in the media than Carlsmed. MarketBeat recorded 5 mentions for Alpha Tau Medical and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.94 beat Alpha Tau Medical's score of 0.50 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
Alpha Tau Medical	Neutral

Summary

Carlsmed beats Alpha Tau Medical on 8 of the 13 factors compared between the two stocks.

How does Carlsmed compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

95.2% of Avanos Medical shares are held by institutional investors. 2.3% of Avanos Medical shares are held by company insiders. Comparatively, 12.9% of Carlsmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Carlsmed has a consensus target price of $18.75, suggesting a potential upside of 58.63%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts clearly believe Carlsmed is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Avanos Medical has a net margin of -10.39% compared to Carlsmed's net margin of -57.76%. Avanos Medical's return on equity of 5.39% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Carlsmed	-57.76%	-60.74%	-29.84%

Carlsmed has lower revenue, but higher earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$701.20M	1.67	-$72.90M	-$1.61	N/A
Carlsmed	$50.51M	6.36	-$29.63M	-$2.51	N/A

In the previous week, Avanos Medical and Avanos Medical both had 1 articles in the media. Avanos Medical's average media sentiment score of 1.28 beat Carlsmed's score of 0.94 indicating that Avanos Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Avanos Medical	Positive
Carlsmed	Positive

Summary

Avanos Medical and Carlsmed tied by winning 7 of the 14 factors compared between the two stocks.

How does Carlsmed compare to Artivion?

Carlsmed (NASDAQ:CARL) and Artivion (NYSE:AORT) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Artivion has a net margin of 2.55% compared to Carlsmed's net margin of -57.76%. Artivion's return on equity of 7.15% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Artivion	2.55%	7.15%	3.63%

86.4% of Artivion shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Carlsmed and Carlsmed both had 1 articles in the media. Carlsmed's average media sentiment score of 0.94 beat Artivion's score of 0.00 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
Artivion	Neutral

Carlsmed presently has a consensus price target of $18.75, indicating a potential upside of 58.63%. Artivion has a consensus price target of $44.17, indicating a potential upside of 71.52%. Given Artivion's stronger consensus rating and higher possible upside, analysts clearly believe Artivion is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Artivion has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	6.36	-$29.63M	-$2.51	N/A
Artivion	$441.33M	2.83	$9.77M	$0.24	107.29

Summary

Artivion beats Carlsmed on 11 of the 14 factors compared between the two stocks.

How does Carlsmed compare to Tandem Diabetes Care?

Carlsmed (NASDAQ:CARL) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Tandem Diabetes Care has a net margin of -9.20% compared to Carlsmed's net margin of -57.76%. Tandem Diabetes Care's return on equity of -53.88% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Carlsmed presently has a consensus price target of $18.75, suggesting a potential upside of 58.63%. Tandem Diabetes Care has a consensus price target of $28.93, suggesting a potential upside of 77.56%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Tandem Diabetes Care had 8 more articles in the media than Carlsmed. MarketBeat recorded 9 mentions for Tandem Diabetes Care and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.94 beat Tandem Diabetes Care's score of 0.94 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
Tandem Diabetes Care	Positive

Carlsmed has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	6.36	-$29.63M	-$2.51	N/A
Tandem Diabetes Care	$1.01B	1.10	-$204.71M	-$1.40	N/A

Summary

Tandem Diabetes Care beats Carlsmed on 9 of the 14 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARL vs. The Competition

Export

Metric	Carlsmed	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$301.21M	$3.15B	$5.09B	$12.67B
Dividend Yield	N/A	N/A	34.29%	8.87%
P/E Ratio	-4.71	22.68	23.66	24.05
Price / Sales	6.36	243.45	132.64	89.73
Price / Cash	N/A	8.96	164.96	59.89
Price / Book	3.18	5.87	11.84	6.23
Net Income	-$29.63M	$23.43M	$121.47M	$331.94M
7 Day Performance	-3.19%	-4.09%	-2.16%	-1.93%
1 Month Performance	11.83%	-7.26%	-2.97%	-0.97%
1 Year Performance	N/A	-24.10%	10.66%	18.24%

Carlsmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARL Carlsmed	2.3034 of 5 stars	$11.82 +6.7%	$18.75 +58.6%	N/A	$301.21M	$50.51M	N/A	100
PRCT PROCEPT BioRobotics	3.1936 of 5 stars	$21.03 flat	$40.00 +90.2%	-67.0%	$1.20B	$308.05M	N/A	430
DRTS Alpha Tau Medical	1.9172 of 5 stars	$13.23 flat	$12.60 -4.8%	+295.6%	$1.20B	N/A	N/A	80	Analyst Forecast
AVNS Avanos Medical	0.7643 of 5 stars	$24.93 0.0%	N/A	+116.6%	$1.17B	$701.20M	N/A	2,287
AORT Artivion	3.702 of 5 stars	$23.91 -0.3%	$44.17 +84.7%	-22.2%	$1.16B	$441.33M	99.63	1,800

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARL) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carlsmed (CARL) Competitors

CARL vs. PRCT, DRTS, AVNS, AORT, and TNDM

How does Carlsmed compare to PROCEPT BioRobotics?

Summary

How does Carlsmed compare to Alpha Tau Medical?

Summary

How does Carlsmed compare to Avanos Medical?

Summary

How does Carlsmed compare to Artivion?

Summary

How does Carlsmed compare to Tandem Diabetes Care?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carlsmed (CARL) Competitors

CARL vs. PRCT, DRTS, AVNS, AORT, and TNDM

How does Carlsmed compare to PROCEPT BioRobotics?

Do institutionals and insiders have more ownership in PRCT or CARL?

Is PRCT or CARL more profitable?

Does the media favor PRCT or CARL?

Which has better valuation & earnings, PRCT or CARL?

Do analysts rate PRCT or CARL?

Summary

How does Carlsmed compare to Alpha Tau Medical?

Is CARL or DRTS more profitable?

Do analysts prefer CARL or DRTS?

Do institutionals & insiders hold more shares of CARL or DRTS?

Which has preferable earnings & valuation, CARL or DRTS?

Does the media favor CARL or DRTS?

Summary

How does Carlsmed compare to Avanos Medical?

Do insiders & institutionals hold more shares of AVNS or CARL?

Do analysts rate AVNS or CARL?

Is AVNS or CARL more profitable?

Which has stronger earnings & valuation, AVNS or CARL?

Does the media favor AVNS or CARL?

Summary

How does Carlsmed compare to Artivion?

Is CARL or AORT more profitable?

Do insiders and institutionals have more ownership in CARL or AORT?

Does the media refer more to CARL or AORT?

Do analysts rate CARL or AORT?

Which has stronger earnings & valuation, CARL or AORT?

Summary

How does Carlsmed compare to Tandem Diabetes Care?

Is CARL or TNDM more profitable?

Do analysts recommend CARL or TNDM?

Does the media favor CARL or TNDM?

Which has higher earnings & valuation, CARL or TNDM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools